Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From GC Pharma

Korea Policies To Shift To Non-COVID Areas In 2022?

The Pink Sheet takes a look back at major policy developments in South Korea in 2021 and ahead at what’s in store for the coming year.

South Korea Pink Sheet Perspectives

Coronavirus Update: Japan Approves Lagevrio, Korea Clears Paxlovid

Oral antivirals make progress in Asia as Japan issues emergency approval to Merck's Lagevrio in a matter of weeks and South Korea clears Pfizer's contender Paxlovid. Vaccines also move forward in both countries with deals for boosters, new supply agreements and the advancement of home-grown candidates.  

Coronavirus COVID-19 Vaccines

First Chinese Rare Disease Biotech IPO To Spark Interest In Less Travelled Path?

CanBridge public listing is expected to generate much needed funding and spotlights a largely untapped but challenging segment.

Rare Diseases Commercial

Korea Q3 Roundup: China Sales, Prescription Drugs, Vaccines Boost Results

Notable third-quarter developments at major Korean pharma firms included the domestic reimbursement of Yuhan’s Leclaza, the approval of Hanmi’s Rolontis and SK Bioscience's approval filing for Novavax's COVID-19 vaccine for supply in the country, a roundup of results by Scrip shows.

South Korea Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Distributors
  • Pharmaceuticals
  • Contract Manufacturing Organization
  • Other Names / Subsidiaries
    • Ceragem Medisys
    • Green Cross LabCell
    • Green Cross Corporation
UsernamePublicRestriction

Register